

Real-World Data for Commercially Available Lifileucel*

This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.

Study	N	ORR	DCR
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma <i>Transplantation and Cellular Therapy, Karapetyan L, et al</i> VIEW	41	44%	73%
Impact of number of IL-2 infusions and product out-of-specification status on outcomes of tumor infiltrating lymphocyte therapy for melanoma <i>AACR 2026, Aboelatta M, et al</i> VIEW	36	50%	72%
Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel <i>Transplantation and Cellular Therapy, Desai A, et al</i> VIEW	23	83%	—
Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients <i>Transplantation and Cellular Therapy, Karapetyan L, et al</i> VIEW	16	44%	62%
Lifileucel Infusions in the Real World: A Single-Institution Series <i>ESMO-IO 2025, Patel S, et al</i> VIEW	~10	70%	—
Characteristics and Outcomes of Real-World Patients with Immunotherapy-Refractory Metastatic Melanoma Referred for Evaluation for Tumor Infiltrating Lymphocyte Therapy <i>ASTCT 2026, Pachori A, et al</i> VIEW	10	50%	60%

*Publications shown are available studies which include response rates.